The National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, awarded a single award Indefinite Delivery Contract to Alchem Laboratories Corporation. The contract has a potential value of $7,777,665 and a period of performance from September 2017 to September 2022.
Under the contract, Alchem Laboratories Corporation provides non-good manufacturing practices synthesis of small molecules to support the National Cancer Institute's research efforts. Delivery orders have been placed for the synthesis of specific compounds, including 100 grams of (R)-N-(6-Chloro-4-((1-phenylethyl)amino)pyrido[3,4-d]pyrimidin-5-yl)methanesulfonamide with a value of $43,887.60 to be completed in October 2022. Other orders include the synthesis of up to ten sample compounds annually from September 2021 to September 2026, valued at $3.28 million. Work is performed in Alachua, Florida.
The original solicitation sought the non-good manufacturing practices synthesis of small molecules to advance the National Cancer Institute's cancer research mission. Delivery orders indicate the contract supports both discrete synthesis of specific compounds as well as ongoing continuity of supply for the National Cancer Institute's research programs. Placed orders demonstrate the prime contractor's performance of diverse small molecule syntheses from milligram to multi-gram quantities.